Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.61
CTRX's Cash to Debt is ranked lower than
59% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.55 vs. CTRX: 0.61 )
Ranked among companies with meaningful Cash to Debt only.
CTRX' s 10-Year Cash to Debt Range
Min: 0.26  Med: 1.50 Max: No Debt
Current: 0.61
Equity to Asset 0.57
CTRX's Equity to Asset is ranked higher than
79% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.36 vs. CTRX: 0.57 )
Ranked among companies with meaningful Equity to Asset only.
CTRX' s 10-Year Equity to Asset Range
Min: 0.3  Med: 0.61 Max: 0.91
Current: 0.57
0.3
0.91
F-Score: 7
Z-Score: 4.57
M-Score: -2.15
WACC vs ROIC
2.00%
7.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 2.70
CTRX's Operating margin (%) is ranked lower than
52% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.79 vs. CTRX: 2.70 )
Ranked among companies with meaningful Operating margin (%) only.
CTRX' s 10-Year Operating margin (%) Range
Min: -32.17  Med: 5.06 Max: 19.04
Current: 2.7
-32.17
19.04
Net-margin (%) 1.51
CTRX's Net-margin (%) is ranked higher than
55% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.50 vs. CTRX: 1.51 )
Ranked among companies with meaningful Net-margin (%) only.
CTRX' s 10-Year Net-margin (%) Range
Min: -41.12  Med: 2.57 Max: 16.86
Current: 1.51
-41.12
16.86
ROE (%) 6.64
CTRX's ROE (%) is ranked higher than
52% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.64 vs. CTRX: 6.64 )
Ranked among companies with meaningful ROE (%) only.
CTRX' s 10-Year ROE (%) Range
Min: -128.77  Med: 10.25 Max: 22.92
Current: 6.64
-128.77
22.92
ROA (%) 3.74
CTRX's ROA (%) is ranked higher than
55% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.93 vs. CTRX: 3.74 )
Ranked among companies with meaningful ROA (%) only.
CTRX' s 10-Year ROA (%) Range
Min: -43.48  Med: 6.60 Max: 12.79
Current: 3.74
-43.48
12.79
ROC (Joel Greenblatt) (%) 225.97
CTRX's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 86.38 vs. CTRX: 225.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CTRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -29.44  Med: 129.51 Max: 665.78
Current: 225.97
-29.44
665.78
Revenue Growth (3Y)(%) 43.60
CTRX's Revenue Growth (3Y)(%) is ranked higher than
92% of the 24 Companies
in the Global Health Care Plans industry.

( Industry Median: 13.30 vs. CTRX: 43.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CTRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -12.5  Med: 29.45 Max: 143.3
Current: 43.6
-12.5
143.3
EBITDA Growth (3Y)(%) 51.50
CTRX's EBITDA Growth (3Y)(%) is ranked higher than
95% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 8.90 vs. CTRX: 51.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CTRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0  Med: 31.00 Max: 56.8
Current: 51.5
0
56.8
EPS Growth (3Y)(%) 33.10
CTRX's EPS Growth (3Y)(%) is ranked higher than
81% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 7.30 vs. CTRX: 33.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CTRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -9.4  Med: 33.10 Max: 55.9
Current: 33.1
-9.4
55.9
» CTRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

CTRX Guru Trades in Q3 2014

Jeremy Grantham 1,654,004 sh (New)
Wallace Weitz 1,001,377 sh (+33.76%)
Diamond Hill Capital 476,976 sh (+17.26%)
Manning & Napier Advisors, Inc 5,328,220 sh (+10.49%)
Pioneer Investments 333,535 sh (unchged)
Vanguard Health Care Fund 4,221,183 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen 270,400 sh (-12.97%)
Paul Tudor Jones 12,455 sh (-20.48%)
Jim Simons 66,600 sh (-83.34%)
» More
Q4 2014

CTRX Guru Trades in Q4 2014

Joel Greenblatt 22,426 sh (New)
Jim Simons 208,970 sh (+213.77%)
Jeremy Grantham 3,028,803 sh (+83.12%)
Paul Tudor Jones 17,792 sh (+42.85%)
Manning & Napier Advisors, Inc 7,315,426 sh (+37.30%)
Vanguard Health Care Fund 4,937,683 sh (+16.97%)
Wallace Weitz 1,162,989 sh (+16.14%)
Pioneer Investments 379,996 sh (+13.93%)
Diamond Hill Capital 505,966 sh (+6.08%)
Steven Cohen Sold Out
» More
Q1 2015

CTRX Guru Trades in Q1 2015

Mario Gabelli 145,800 sh (New)
Paul Tudor Jones 218,880 sh (+1130.22%)
Diamond Hill Capital 590,081 sh (+16.62%)
Pioneer Investments 427,011 sh (+12.37%)
Jeremy Grantham 3,314,869 sh (+9.44%)
Wallace Weitz 1,177,876 sh (+1.28%)
Vanguard Health Care Fund Sold Out
Manning & Napier Advisors, Inc 2,208,429 sh (-69.81%)
Joel Greenblatt 5,390 sh (-75.97%)
Jim Simons 30,000 sh (-85.64%)
» More
Q2 2015

CTRX Guru Trades in Q2 2015

Louis Moore Bacon 40,000 sh (New)
Eric Mindich 5,681,000 sh (New)
Prem Watsa 16,500 sh (New)
Jim Simons 877,670 sh (+2825.57%)
Paul Tudor Jones 604,390 sh (+176.13%)
Mario Gabelli 261,700 sh (+79.49%)
Diamond Hill Capital 641,994 sh (+8.80%)
Joel Greenblatt Sold Out
Pioneer Investments Sold Out
Manning & Napier Advisors, Inc Sold Out
Wallace Weitz 630,219 sh (-46.50%)
Jeremy Grantham 491,270 sh (-85.18%)
» More
» Details

Insider Trades

Latest Guru Trades with CTRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 42.60
CTRX's P/E(ttm) is ranked lower than
94% of the 17 Companies
in the Global Health Care Plans industry.

( Industry Median: 25.00 vs. CTRX: 42.60 )
Ranked among companies with meaningful P/E(ttm) only.
CTRX' s 10-Year P/E(ttm) Range
Min: 2.84  Med: 33.50 Max: 78.05
Current: 42.6
2.84
78.05
Forward P/E 21.60
CTRX's Forward P/E is ranked lower than
87% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.56 vs. CTRX: 21.60 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 42.60
CTRX's PE(NRI) is ranked lower than
94% of the 17 Companies
in the Global Health Care Plans industry.

( Industry Median: 25.00 vs. CTRX: 42.60 )
Ranked among companies with meaningful PE(NRI) only.
CTRX' s 10-Year PE(NRI) Range
Min: 2.83  Med: 33.21 Max: 77.62
Current: 42.6
2.83
77.62
P/B 2.46
CTRX's P/B is ranked higher than
63% of the 27 Companies
in the Global Health Care Plans industry.

( Industry Median: 2.67 vs. CTRX: 2.46 )
Ranked among companies with meaningful P/B only.
CTRX' s 10-Year P/B Range
Min: 1.58  Med: 2.55 Max: 8.41
Current: 2.46
1.58
8.41
P/S 0.64
CTRX's P/S is ranked lower than
54% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.60 vs. CTRX: 0.64 )
Ranked among companies with meaningful P/S only.
CTRX' s 10-Year P/S Range
Min: 0.42  Med: 1.04 Max: 6.67
Current: 0.64
0.42
6.67
PFCF 27.46
CTRX's PFCF is ranked lower than
85% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 14.61 vs. CTRX: 27.46 )
Ranked among companies with meaningful PFCF only.
CTRX' s 10-Year PFCF Range
Min: 10.38  Med: 25.69 Max: 97.6
Current: 27.46
10.38
97.6
POCF 24.08
CTRX's POCF is ranked lower than
89% of the 19 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.50 vs. CTRX: 24.08 )
Ranked among companies with meaningful POCF only.
CTRX' s 10-Year POCF Range
Min: 8.78  Med: 21.16 Max: 65.29
Current: 24.08
8.78
65.29
EV-to-EBIT 24.66
CTRX's EV-to-EBIT is ranked lower than
85% of the 20 Companies
in the Global Health Care Plans industry.

( Industry Median: 10.75 vs. CTRX: 24.66 )
Ranked among companies with meaningful EV-to-EBIT only.
CTRX' s 10-Year EV-to-EBIT Range
Min: 9.9  Med: 21.95 Max: 64.6
Current: 24.66
9.9
64.6
PEG 0.97
CTRX's PEG is ranked higher than
87% of the 15 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.89 vs. CTRX: 0.97 )
Ranked among companies with meaningful PEG only.
CTRX' s 10-Year PEG Range
Min: 0.53  Med: 1.00 Max: 43.6
Current: 0.97
0.53
43.6
Shiller P/E 79.66
CTRX's Shiller P/E is ranked lower than
100% of the 17 Companies
in the Global Health Care Plans industry.

( Industry Median: 27.70 vs. CTRX: 79.66 )
Ranked among companies with meaningful Shiller P/E only.
CTRX' s 10-Year Shiller P/E Range
Min: 7.81  Med: 50.38 Max: 116.44
Current: 79.66
7.81
116.44
Current Ratio 1.38
CTRX's Current Ratio is ranked higher than
60% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.30 vs. CTRX: 1.38 )
Ranked among companies with meaningful Current Ratio only.
CTRX' s 10-Year Current Ratio Range
Min: 0.91  Med: 2.52 Max: 9.01
Current: 1.38
0.91
9.01
Quick Ratio 1.38
CTRX's Quick Ratio is ranked higher than
60% of the 25 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.29 vs. CTRX: 1.38 )
Ranked among companies with meaningful Quick Ratio only.
CTRX' s 10-Year Quick Ratio Range
Min: 0.84  Med: 2.24 Max: 8.99
Current: 1.38
0.84
8.99
Days Sales Outstanding 24.16
CTRX's Days Sales Outstanding is ranked higher than
50% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 24.16 vs. CTRX: 24.16 )
Ranked among companies with meaningful Days Sales Outstanding only.
CTRX' s 10-Year Days Sales Outstanding Range
Min: 17.64  Med: 58.98 Max: 92.51
Current: 24.16
17.64
92.51

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.62
CTRX's Price/Projected FCF is ranked lower than
71% of the 21 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.07 vs. CTRX: 1.62 )
Ranked among companies with meaningful Price/Projected FCF only.
CTRX' s 10-Year Price/Projected FCF Range
Min: 1.08  Med: 2.08 Max: 6.34
Current: 1.62
1.08
6.34
Price/DCF (Earnings Based) 1.50
CTRX's Price/DCF (Earnings Based) is ranked lower than
78% of the 9 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.17 vs. CTRX: 1.50 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.58
CTRX's Price/Median PS Value is ranked higher than
82% of the 28 Companies
in the Global Health Care Plans industry.

( Industry Median: 0.92 vs. CTRX: 0.58 )
Ranked among companies with meaningful Price/Median PS Value only.
CTRX' s 10-Year Price/Median PS Value Range
Min: 0.21  Med: 0.90 Max: 6.27
Current: 0.58
0.21
6.27
Price/Peter Lynch Fair Value 1.51
CTRX's Price/Peter Lynch Fair Value is ranked higher than
54% of the 13 Companies
in the Global Health Care Plans industry.

( Industry Median: 1.70 vs. CTRX: 1.51 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CTRX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.29  Med: 1.47 Max: 4.69
Current: 1.51
0.29
4.69
Earnings Yield (Greenblatt) (%) 4.10
CTRX's Earnings Yield (Greenblatt) (%) is ranked lower than
59% of the 29 Companies
in the Global Health Care Plans industry.

( Industry Median: 6.50 vs. CTRX: 4.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CTRX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.5  Med: 4.60 Max: 10.1
Current: 4.1
1.5
10.1
Forward Rate of Return (Yacktman) (%) 51.17
CTRX's Forward Rate of Return (Yacktman) (%) is ranked higher than
88% of the 17 Companies
in the Global Health Care Plans industry.

( Industry Median: 16.71 vs. CTRX: 51.17 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CTRX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -23.6  Med: 40.30 Max: 52.5
Current: 51.17
-23.6
52.5

Analyst Estimate

Dec15 Dec16 Dec17
EPS($) 3.26 3.70 4.14
EPS without NRI($) 3.26 3.70 4.14

Business Description

Industry: Health Care Plans » Health Care Plans
Compare: » details
Traded in other countries:CCT.Canada,
Catamaran Corp is a provider of pharmacy benefit management services PBM and healthcare IT solutions to the healthcare benefit management industry. The Company's PBM services include electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail service pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, preferred drug management programs, drug review and analysis, consulting services, data access, and reporting and information analysis. The Company owns a mail service pharmacy and a specialty service pharmacy ('Ascend'). PBM services such as pharmacy network management could be provided to the company's customers using the Company's own system software and services. It provides on-line transaction processing solutions through web-enabled, real-time transaction processing technology. The Company's informed Rx offering is a suite of a la carte PBM services that provide a flexible and cost-effective alternative to traditional PBM offerings typically employed by health plans, government agencies and employers. It also provides a pharmacy spend management solutions and information technology capabilities. RxCLAIM (r) is an on-line transaction processing system designed to provide instant on-line adjudication of third-party prescription drug claims at the point of service, including trouble-free claims management and cost-effective review, as well as payment and billing support and real-time functionality for updating benefit, price, member, provider and drug details. RxCLAIM is designed to provide the company's customers with automation efficiencies, flexibility and control by facilitating the real-time processing of pharmacy claims and payments against eligibility, plan benefits, formularies, price, drug utilization review, prior authorization and rebates in addition to many other features. It is also a provider of HCIT solutions and services to providers, payers and other participants in the pharmaceutical supply chain in North America. SXC's product offerings include a range of software products for managing prescription drug programs and for drug prescribing and dispensing. The Company's solutions are available on a license basis with on-going maintenance and support or on a transaction fee basis using an ASP model. The Company's provider customers include independent, regional chain, institutional, and mail-order pharmacies. It is subject to state and federal statutes and regulations governing the operation of mail service pharmacies and the dispensing of controlled substances.
» More Articles for CTRX

Headlines

Articles On GuruFocus.com
Taconic Capital Buys Time Warner Cable, Broadcom Aug 23 2015 
Prem Watsa Buys 8 New Diverse Holdings in Second Quarter Aug 14 2015 
Weekly 52-Week Highs Highlight: CTSH, CMG, CTRX, MA Aug 11 2015 
Predictable and Undervalued Companies - Part IV Jul 07 2015 
CVS Eyeing Omnicare Acquisition To Bolster Market Position May 23 2015 
UnitedHealth Group Is Ready For A Huge Pharmacy Deal Apr 06 2015 
M&A’s Driving The Stock Indexes Ahead Apr 06 2015 
UnitedHealth Planning Catamaran Corp’s Acquisition For $12.78 Billion Apr 02 2015 
Gilead Sciences Offering Fresh Wave Of Competition To AbbVie’s Viekira Pak Feb 06 2015 
Wallace Weitz's Partners Value Fund Q2 Commentary Oct 06 2014 

More From Other Websites
Hedges Funds Are Hoarding Shares Of These Mid-caps Aug 31 2015
Prem Watsa Buys 8 Diverse New Holdings in Second Quarter Aug 14 2015
Apple Inc. (AAPL) Jumps to Second Spot in Sprott’s Equity Portfolio Aug 03 2015
UNITEDHEALTH GROUP INCORPORATED Financials Jul 28 2015
UnitedHealth Still Undervalued Despite Big Runup Jul 26 2015
JD.com, Inc. to Join the NASDAQ-100 Index Beginning July 29, 2015 Jul 23 2015
CATAMARAN CORP Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of... Jul 23 2015
Optumrx, Catamaran Complete Combination Jul 23 2015
OptumRx, Catamaran Complete Combination Jul 23 2015
Catamaran Corporation to be Removed From the NASDAQ-100 Index Beginning July 24, 2015 Jul 23 2015
UnitedHealth Raises Over $10 Billion to Fund Catamaran Buyout Jul 21 2015
UnitedHealth Group Incorporated -- Moody's rates UnitedHealth Group's senior notes A3; negative... Jul 20 2015
UnitedHealth Group (UNH) Earnings Report: Q2 2015 Conference Call Transcript Jul 16 2015
With One Billion Prescriptions, UnitedHealth Prescribes Future PBM Growth Jul 16 2015
What to watch from UnitedHealth earnings Jul 15 2015
CATAMARAN CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other... Jul 15 2015
Catamaran Shareholders Approve Acquisition by UnitedHealth Group Jul 14 2015
Catamaran Shareholders Approve Acquisition by UnitedHealth Group Jul 14 2015
CATAMARAN CORP Files SEC form 8-K, Other Events Jul 02 2015
What Is the Pharmacy Benefit Management Industry? Jul 02 2015
Catamaran and Health New England Partnership Reduces Same-Cause Hospital Readmissions by More Than... Jun 25 2015
Catamaran and Health New England Partnership Reduces Same-Cause Hospital Readmissions by More Than... Jun 25 2015
UnitedHealth hikes forecast, shares edge to new heights Apr 16 2015
UnitedHealth hits all the notes, shares head for new heights Apr 16 2015
UnitedHealth bulks up for prescription drug cost battle Mar 30 2015
US stocks move higher, led by gains in energy companies Mar 30 2015
UnitedHealth to buy pharmacy benefit firm Catamaran for $12.8 billion Mar 30 2015
US stocks open higher, led by gains in energy companies Mar 30 2015
UnitedHealth to buy pharmacy benefits manager Catamaran Mar 30 2015
Ahead of the Bell: Catamaran climbs after earnings report Feb 26 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK